DB
VTGN icon

Dmitry Balyasny’s VistaGen Therapeutics VTGN Stock Holding History

Dmitry Balyasny’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,726
Closed -$8.42K – 3196
2022
Q4 		$8.42K Buy
2,726
+1,573
+136% +$5.92K ﹤0.01% 2581
2022
Q3 		$5K Buy
+1,153
New +$11.4K ﹤0.01% 2712

Other funds holding VTGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dmitry Balyasny's VTGN Position: Q1 2023 in Review

Dmitry Balyasny sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 2,726 shares — an estimated $8.42K sold.

Dmitry Balyasny first reported a position in VTGN in Q3 2022 and held it in 2 quarters. The position peaked at $8.42K in Q4 2022. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • Dmitry Balyasny reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 2,726 VistaGen Therapeutics shares in Q1 2023, an estimated $8.42K.
  • Dmitry Balyasny first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 2 quarters.
  • Dmitry Balyasny's VistaGen Therapeutics position peaked at $8.42K in Q4 2022.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.